New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. ÌýYou can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
WELCOME BACK
Neuronal alpha-Synuclein Disease Integrated Staging System performance in PPMI, PASADENA, and SPARK baseline cohorts.
ÌÇÐÄ´«Ã½
Neuronal alpha-Synuclein Disease Integrated Staging System performance in PPMI, PASADENA, and SPARK baseline cohorts. medRxiv : the preprint server for health sciences Dam, T., Pagano, G., Brumm, M. C., Gochanour, C., Poston, K. L., Weintraub, D., Chahine, L. M., Coffey, C., Tanner, C. M., Kopil, C. M., Xiao, Y., Chowdhury, S., Concha-Marambio, L., DiBiaso, P., Foroud, T., Frasier, M., Jennings, D., Kieburtz, K., Merchant, K., Mollenhauer, B., Montine, T. J., Nudelman, K., Seibyl, J., Sherer, T., Singleton, A., Stephenson, D., Stern, M., Soto, C., Tolosa, E., Siderowf, A., Dunn, B., Simuni, T., Marek, K. 2024Abstract
The Neuronal alpha-Synuclein Disease (NSD) biological definition and Integrated Staging System (NSD-ISS) provide a ÌÇÐÄ´«Ã½ framework to identify individuals with Lewy body pathology and stage them based on underlying biology and increasing degree of functional impairment. Utilizing data from the PPMI, PASADENA and SPARK studies, we developed and applied biologic and clinical data-informed definitions for the NSD-ISS across the disease continuum. Individuals enrolled as Parkinson's disease, Prodromal, or Healthy Controls were defined and staged based on biological, clinical, and functional anchors at baseline. Across the three studies 1,741 participants had SAA data and of these 1,030 (59%) were S+ consistent with NSD. Among sporadic PD, 683/736 (93%) were NSD, and the distribution for Stages 2B, 3, and 4 was 25%, 63%, and 9%, respectively. Median (95% CI) time to developing a clinically meaningful outcome was 8.3 (6.2, 10.1), 5.9 (4.1, 6.0), and 2.4 (1.0, 4.0) years for baseline stage 2B, 3, and 4, respectively. We propose pilot biologic and clinical anchors for NSD-ISS. Our results highlight the baseline heterogeneity of individuals currently defined as early PD. Baseline stage predicts time to progression to clinically meaningful milestones. Further ÌÇÐÄ´«Ã½ on validation of the anchors in longitudinal cohorts is necessary.
View details for
View details for
View details for